Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker TEVA
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 3, 2026 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 29, 2026 | TEVA Teva Pharmaceutical Industries Limited | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Sep 16, 2026 | TEVA Teva Pharmaceutical Industries Limited | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Sep 16, 2026 | TEVA Teva Pharmaceutical Industries Limited | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Sep 14, 2026 | TEVA Teva Pharmaceutical Industries Limited | 8.01 Other Events | 8-K | 8-K ↗ |
| Sep 11, 2026 | TEVA Teva Pharmaceutical Industries Limited | 8.01 Other Events | 8-K | 8-K ↗ |
| Sep 11, 2026 | TEVA Teva Pharmaceutical Industries Limited | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Sep 3, 2026 | TEVA Teva Pharmaceutical Industries Limited | 8.01 Other Events | 8-K | 8-K ↗ |
| Sep 3, 2026 | TEVA Teva Pharmaceutical Industries Limited | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Jul 29, 2026 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 28, 2026 | TEVA Teva Pharmaceutical Industries Limited | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Apr 29, 2026 | TEVA Teva Pharmaceutical Industries Limited | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Apr 29, 2026 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 28, 2026 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 12, 2026 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Dec 11, 2025 | TEVA Teva Pharmaceutical Industries Limited | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Dec 11, 2025 | TEVA Teva Pharmaceutical Industries Limited | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 5, 2025 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 30, 2025 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 5, 2025 | TEVA Teva Pharmaceutical Industries Limited | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 28, 2025 | TEVA Teva Pharmaceutical Industries Limited | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| May 28, 2025 | TEVA Teva Pharmaceutical Industries Limited | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 22, 2025 | TEVA Teva Pharmaceutical Industries Limited | 8.01 Other Events | 8-K | 8-K ↗ |
| May 22, 2025 | TEVA Teva Pharmaceutical Industries Limited | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 7, 2025 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 29, 2025 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 12, 2024 | TEVA Teva Pharmaceutical Industries Limited | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Nov 6, 2024 | TEVA Teva Pharmaceutical Industries Limited | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
28 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:23 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances